Leukemia

Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 24, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Status: Withdrawn application

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Status: Withdrawn application

Key Points: 


Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Status: Withdrawn application

Service Experts Works with Make-A-Wish to Grant Wish for Phoenix Tween

Retrieved on: 
Monday, December 18, 2023

Richardson, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Continuing a successful seven-year partnership with Make-A-Wish®, Service Experts worked with Orangutan, its Phoenix service center, to grant the wish for Jacob, a 12-year-old with Leukemia.

Key Points: 
  • Richardson, Texas, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Continuing a successful seven-year partnership with Make-A-Wish®, Service Experts worked with Orangutan, its Phoenix service center, to grant the wish for Jacob, a 12-year-old with Leukemia.
  • Jacob is immunocompromised and cannot leave the house frequently, so he wished for a computer with a gaming set-up, which Service Experts was happy to give him.
  • A wish renews hope, uplifts spirits and encourages the belief in the impossible, giving kids the strength to fight against—and even overcome—a critical illness.
  • "A wish creates an immediate turning point in a child's treatment and recovery, and partnerships like the one with Service Experts are critical to helping us deliver that life-changing impact," said Leslie Motter, president and CEO of Make-A-Wish America.

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

Retrieved on: 
Monday, December 11, 2023

Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

Key Points: 
  • Data to be presented today (abstract: 4853 ) at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.
  • Please use this link to participate in the live call; a listen-only version of the webcast is available here .
  • “Leukemic relapse is the leading cause of death in patients undergoing HSCT and prevention of relapse remains a high unmet need.
  • In this trial, the first three patients were high-risk or relapsed AML patients with complex cytogenetics.

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023

WATERTOWN, Mass., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new data from its ongoing KT-333 Phase 1 trial. KT-333, a first-in-class, potent, highly selective, heterobifunctional small molecule degrader of STAT3, demonstrated early signs of antitumor activity at doses that were generally well-tolerated and associated with substantial STAT3 knockdown in blood and tumor. The data were presented at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition taking place from December 9-12, 2023, in San Diego, California.

Key Points: 
  • The data were presented at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition taking place from December 9-12, 2023, in San Diego, California.
  • The poster provides an interim update with a data cut-off as of October 18, 2023.
  • Dr. Aditi Shastri from Montefiore Medical Center and Albert Einstein College of Medicine, a lead investigator in the study, presented the interim Phase 1 findings.
  • Preclinical data demonstrating the potential of STAT3 protein degraders as a therapeutic approach in venetoclax-resistant Acute Myeloid Leukemia was also presented at the meeting.

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Retrieved on: 
Sunday, December 10, 2023

PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology (ASH 2023) for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.

Key Points: 
  • “We are excited to share new preclinical data for VIP943 and VIP94 with our stakeholders,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • Poster #1435: Selectivity and Safety of VIP943: A novel CD123 Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class.
  • Objective: The poster outlines a series of assays used to characterize the preclinical properties of VIP943, including biochemistry, pharmacology, on-target selectivity and activity, safety, and toxicokinetics.
  • Complete blood counts (CBCs) show that VIP924 had minimal impact on the six elements of the CBC reported in these studies.

Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

Retrieved on: 
Friday, December 8, 2023

“We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.

Key Points: 
  • “We are honored to be designated for the PedAL initiative, marking Kura’s continued development of ziftomenib for the treatment of acute leukemias,” said Mollie Leoni, M.D., Executive Vice President, Clinical Development.
  • “Kura remains committed to developing new treatment options across the continuum of care, including for pediatric patients with acute leukemias where poor outcomes and significant unmet medical need remain.
  • PedAL is a pioneering global master clinical trial for Pediatric Acute Leukemia, founded and led by LLS, which aims to advance more effective, safer treatments with fewer long-term side effects, for children with blood cancer.
  • Kura will supply LLS and the Princess Máxima Center with ziftomenib for the study.

Bionano Announces Presentations Featuring OGM Utility Across Blood Cancer Research at the American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, December 6, 2023

ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease.

Key Points: 
  • ASH’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in the field of blood disease.
  • The ASH conference will be held December 9-12, 2023, in San Diego, California and online.
  • 13 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.
  • Unless otherwise noted below, posters will be available to view at the Manchester Grand Hyatt Harbor Ballroom.